Replies to post #140793 on Biotech Values

[ilpapa]

Where does this iteration of HIFU stand in the FDA approval process?

[mcbio]

EDAP: New treatment for prostate cancer gives 'perfect results' for nine in ten men:

EDAP is the most undervalued biotech I follow. 13 million shares OS trades at $1.88, positive cash flow and will file NDA later this yeat for revolutionary cancer treatment.
This was $10 a few years back on anticipation of US filing and now its almost here.

All sounds too good to be true for stock with only $25M market cap. I'd be curious to hear the bear side to this story (there is always one).